Atorlip 10: Effective LDL Cholesterol Reduction for Cardiovascular Health
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.79 | $47.30 (0%) | 🛒 Add to cart |
| 90 | $0.73 | $70.95 $65.36 (8%) | 🛒 Add to cart |
| 120 | $0.70 | $94.60 $83.42 (12%) | 🛒 Add to cart |
| 180 | $0.66 | $141.90 $119.54 (16%) | 🛒 Add to cart |
| 270 | $0.64 | $212.85 $172.86 (19%) | 🛒 Add to cart |
| 360 | $0.63
Best per pill | $283.80 $227.04 (20%) | 🛒 Add to cart |
Atorlip 10 contains atorvastatin calcium, a potent lipid-lowering agent belonging to the statin class. This medication is specifically formulated to manage elevated levels of low-density lipoprotein (LDL) cholesterol, triglycerides, and apolipoprotein B in adult patients. By competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, Atorlip 10 enhances the liver’s ability to clear LDL from the bloodstream. It is indicated as an adjunct to diet and lifestyle modifications for primary and secondary prevention of cardiovascular events. Clinical studies demonstrate its efficacy in reducing the risk of myocardial infarction, stroke, and revascularization procedures in appropriate patient populations.
Features
- Active ingredient: Atorvastatin calcium 10 mg
- Pharmaceutical form: Film-coated tablets
- Mechanism: Selective, competitive inhibition of HMG-CoA reductase
- Bioavailability: Approximately 14% following oral administration
- Protein binding: ≥98% to plasma proteins
- Metabolism: Primarily hepatic via CYP3A4
- Elimination half-life: Approximately 14 hours
- Excretion: Primarily biliary; <2% renal excretion
- Manufacturer compliance: Current Good Manufacturing Practice (cGMP) certified
- Packaging: Blister strips in quantities of 10, 30, or 90 tablets
Benefits
- Significantly reduces LDL cholesterol levels by 35-50% at the 10 mg dosage
- Lowers triglyceride concentrations by 20-40% in hypertriglyceridemic patients
- Increases high-density lipoprotein (HDL) cholesterol by 5-10%
- Demonstrates proven reduction in cardiovascular morbidity and mortality
- Provides 24-hour lipid-lowering effect with once-daily dosing
- Offers flexible dosing options for individualized lipid management
Common use
Atorlip 10 is primarily prescribed for patients with primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) and mixed dyslipidemia. It is indicated for adults who require pharmacological intervention despite adequate trial of diet and other non-pharmacological measures. The medication is also used in patients with established cardiovascular disease to reduce the risk of non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, and angina. Additionally, it may be prescribed for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments.
Dosage and direction
The recommended starting dose is Atorlip 10 once daily, which may be adjusted based on lipid response and tolerability. Dosage range extends from 10 mg to a maximum of 80 mg daily. Administration may occur at any time of day, with or without food, though consistency in timing is recommended. The tablet should be swallowed whole with a glass of water and not crushed or chewed. Dose adjustments should occur at intervals of 2-4 weeks, with periodic lipid monitoring to assess therapeutic response. For patients requiring coadministration with CYP3A4 inhibitors, dose reduction or alternative therapy may be necessary.
Precautions
Liver function tests should be performed before initiation and periodically during treatment. Patients should report any unexplained muscle pain, tenderness, or weakness promptly. Caution is advised in patients with history of liver disease, excessive alcohol consumption, or renal impairment. Blood glucose levels should be monitored as statins may increase HbA1c and fasting serum glucose levels. Elderly patients may require closer monitoring due to potential age-related decreases in hepatic, renal, or cardiac function. Patients should be advised to avoid consuming large quantities of grapefruit juice (>1.2 liters daily) due to potential interaction.
Contraindications
Atorlip 10 is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal. It should not be used during pregnancy, lactation, or in women of childbearing potential not using adequate contraception. Contraindications include hypersensitivity to atorvastatin or any component of the formulation. Concurrent use with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, clarithromycin, or HIV protease inhibitors is prohibited. The medication is contraindicated in patients with a history of myopathy or rhabdomyolysis with other statins.
Possible side effect
Common adverse reactions (≥2%) include headache, myalgia, arthralgia, nausea, diarrhea, constipation, and elevated liver enzymes. Less frequent side effects may include insomnia, nightmares, dizziness, blurred vision, tinnitus, and gastrointestinal disturbances. Serious but rare adverse effects include rhabdomyolysis with renal failure, hepatotoxicity, immune-mediated necrotizing myopathy, and cognitive impairment. Approximately 1-3% of patients may experience creatine kinase elevations. Allergic reactions including rash, pruritus, urticaria, and anaphylaxis have been reported in post-marketing experience.
Drug interaction
Significant interactions occur with strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors), which may increase atorvastatin exposure up to 8-fold. Moderate inhibitors (erythromycin, fluconazole, verapamil) may increase exposure 3-4 fold. Concurrent use with gemfibrozil increases atorvastatin concentration approximately 2-fold. Bile acid sequestrants may decrease atorvastatin bioavailability; administration should be separated by at least 2 hours. Warfarin coadministration may potentiate anticoagulant effect requiring INR monitoring. Interactions with oral contraceptives containing norethindrone and ethinyl estradiol may increase hormone concentrations.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistency in dosing is important for maintaining stable lipid-lowering effects, but occasional missed doses are unlikely to significantly impact long-term efficacy. Patients should be educated about maintaining regular dosing patterns and using reminder systems if necessary.
Overdose
There is no specific antidote for atorvastatin overdose. Reported cases have been asymptomatic or associated with mild gastrointestinal symptoms. In the event of overdose, symptomatic and supportive measures should be instituted. Liver function and creatine kinase levels should be monitored. Due to extensive protein binding, hemodialysis is not expected to enhance elimination. Rhabdomyolysis and renal impairment are potential complications of massive overdose. Medical toxicology consultation is recommended for significant ingestions. Animal studies suggest the LD50 exceeds 2000 mg/kg.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from light and moisture. Keep in the original container with the lid tightly closed. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, preferably through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Healthcare professionals should exercise clinical judgment when prescribing Atorlip 10 based on individual patient characteristics and current treatment guidelines. Patients should not alter their dosage or discontinue medication without consulting their healthcare provider. The full prescribing information should be consulted before initiating therapy. This product is available by prescription only and should be used under appropriate medical supervision.
Reviews
Clinical trials demonstrate that Atorvastatin 10 mg achieves LDL-C reduction goals in approximately 60-70% of patients with primary hypercholesterolemia. The ASTEROID trial showed regression of coronary atherosclerosis with intensive statin therapy. The SPARCL trial demonstrated a 16% relative risk reduction in stroke among patients with recent stroke or TIA. Meta-analyses of major statin trials confirm a 21% reduction in major vascular events per 1 mmol/L reduction in LDL cholesterol. Real-world evidence supports maintained efficacy and generally favorable tolerability profile in diverse patient populations over extended treatment periods.